No abstract

No abstract

Introduction: This study assumes significance as it compares head on DPP-IV inhibitors along with other oral hypoglycemic agents with respect to glycemic and non-glycemic targets. Study was done to evaluate the DPP-IV inhibitors and other oral hypoglycemic agents (OHA) either alone or in combination, with reference to glycemic targets like fasting plasma glucose (FPG), post prandial glucose (PPG) and glycosylated hemoglobin (HbA 1c) in type 2 diabetes mellitus. Material and Methods: This was an open labelled comparative study and included 90 patients with Type 2 DM. These patients were divided into 3groups: Each group was containing 30 patients i.e. Group A: DPP-IV inhibitors (n= 30); Group B: Oral hypoglycemic agents other than DPP-IV inhibitors (n= 30) and Group C: DPP-IV inhibitors + other oral hypoglycemic agents (n= 30). The patients were given drugs on the basis of physician's discretion, depending upon the glycemic of the patients at the time of presentation. A detailed history regarding age, sex, profession, duration of disease, treatment history, family history and personal history was taken for each patient. After stabilization patients observed at 0 weeks, 6 weeks, 12 weeks and 24 weeks. Results: Mean duration of diabetes was 5.35±0.53 years, and the mean age of onset of diabetes was 46.98±0.91years. There was no significant difference between the study groups with respect to FPG, PPG, and HbA1c levels. The HbA1c showed significant improvement in each group at the end of study period. Conclusion: In summary, this study showed that treatment with sitagliptin, either alone or in combination with other oral hypoglycemic agent led to clinically meaningful reductions in HbA1c, FPG and PPG over a 24 week period. Sitagliptin presents an alternative therapeutic strategy for patients with type 2 diabetes and, in general, showed significant improvements in glycemic control and is well tolerated, particularly with regard to weight change and hypoglycemia.